Mutual of America Capital Management LLC Grows Position in Bristol Myers Squibb Company $BMY

Key Points

• Mutual of America Capital Management LLC has increased its holdings in Bristol Myers Squibb by 2.8%, owning 261,932 shares valued at approximately $12.1 million.
• Several institutional investors, such as United Bank and Foster & Motley Inc., also significantly boosted their positions in Bristol Myers Squibb during the same quarter.
• The stock has a consensus rating of "Hold" among analysts, with an average price target set at $57.23.

Mutual of America Capital Management LLC lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 261,932 shares of the biopharmaceutical company's stock after purchasing an additional 7,051 shares during the quarter. Mutual of America Capital Management LLC's holdings in Bristol Myers Squibb were worth $12,125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. United Bank boosted its holdings in Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,277 shares during the period. Koshinski Asset Management Inc. boosted its holdings in Bristol Myers Squibb by 6.7% during the 2nd quarter. Koshinski Asset Management Inc. now owns 27,695 shares of the biopharmaceutical company's stock valued at $1,282,000 after acquiring an additional 1,739 shares during the period. Foster & Motley Inc. boosted its holdings in Bristol Myers Squibb by 34.7% during the 2nd quarter. Foster & Motley Inc. now owns 51,493 shares of the biopharmaceutical company's stock valued at $2,384,000 after acquiring an additional 13,268 shares during the period. Kanawha Capital Management LLC boosted its holdings in Bristol Myers Squibb by 1.5% during the 2nd quarter. Kanawha Capital Management LLC now owns 37,751 shares of the biopharmaceutical company's stock valued at $1,748,000 after acquiring an additional 557 shares during the period. Finally, Chevy Chase Trust Holdings LLC boosted its holdings in Bristol Myers Squibb by 1.0% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,092,316 shares of the biopharmaceutical company's stock valued at $50,563,000 after acquiring an additional 10,639 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on BMY shares. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Dbs Bank raised Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $57.23.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.07% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $43.63 on Monday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The firm has a market capitalization of $88.80 billion, a PE ratio of 17.59, a price-to-earnings-growth ratio of 2.27 and a beta of 0.33. The stock's 50-day simple moving average is $46.07 and its 200-day simple moving average is $47.40.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the company earned $2.07 EPS. The business's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.